SREBF1 and metabolic dysfunction-associated steatotic liver disease: A previous study also suggested that restoring Sirt1 expressioncould become a promising therapeutic strategy for NAFLD (Colak et al., 2014) due to the probable association between Sirt1 and lipid metabolic genes, such as SREBP1, FASN, and SCD1 (Wang et al., 2017; Sun et al., 2015).